SOUTH AFRICA – Aspen Pharmacare Holdings has added nearly US$ 308.5m to its value after the South African pharmaceutical company said it had invested millions of dollars to manufacture the investigational Covid-19 vaccine with US giant Johnson & Johnson.

Aspen through its wholly-owned South African subsidiary, Aspen Pharmacare, had entered into a preliminary agreement with Janssen Pharmaceuticals Inc and Janssen Pharmaceutica NV – two of the Janssen Pharmaceutical companies of Johnson & Johnson – for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate, Ad26.CoV2-S.

The vaccine candidate is undergoing clinical trials at the existing sterile facility in Port Elizabeth.

Aspen chief executive Stephen Saad said the group planned to be a key part of the efforts to find a vaccine for a pandemic that had killed hundreds of thousands of people across the globe.

Saad added that the group would utilise all its resources to aid with patients in need across the world from their South African base.

“We have invested globally in our sterile capability and are determined to play a role in the manufacture of vaccines to add to our proud track record of making contributions to humanity in times of global pandemics,” Saad said.

“This has included, inter alia, being a leading global supplier for antiretrovirals for the treatment of HIV/Aids, multi-drug-resistant-TB products and Covid-19-related treatments, such as anaesthetics and dexamethasone. We have been selected as a vaccine partner by Johnson & Johnson, and this project will receive priority focus” he added.

Saad stressed that Aspen would perform formulation, filling, and secondary packaging of the vaccine for supply to Johnson & Johnson.

He said the agreement was, however, subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.

“The announcement is positive on two fronts. First, it is the potential for increased business, and second, it is a vote of confidence from one of the biggest pharma companies in the world. The way I understand it, Aspen has already spent US$185million on the facility, but it is also worth noting that an agreement has not been signed yet,” Treherne said.

The group further said it would provide the necessary capacity required for the manufacture of Johnson & Johnson’s Covid-19 vaccine candidate.

It said it had invested in excess of US$185m in the facility together with the high technology equipment and systems that would be used to manufacture state-of-the-art sterile drugs and vaccines, packaged into vials, ampoules and pre-filled syringes.

The group said the area where it is intended to develop the vaccine candidate would have capacity to produce more than 300 million doses a year.

Nesan Nair, a senior portfolio manager at Sasfin Securities, said the development boosted Aspen’s net worth.

“It is great news both for the fight against the Covid-19 pandemic and for Aspen as well as for the fact that this vaccine will also be manufactured in South Africa,” Nair said.

Liked this article? Subscribe to DealStreet Africa News, our regular email newsletter with the latest news, deals and insights from Africa’s businesseconomy and more. SUBSCRIBE